JP2017537940A - 増殖性疾患の処置に有用な融合1,3−アゾール誘導体 - Google Patents

増殖性疾患の処置に有用な融合1,3−アゾール誘導体 Download PDF

Info

Publication number
JP2017537940A
JP2017537940A JP2017531478A JP2017531478A JP2017537940A JP 2017537940 A JP2017537940 A JP 2017537940A JP 2017531478 A JP2017531478 A JP 2017531478A JP 2017531478 A JP2017531478 A JP 2017531478A JP 2017537940 A JP2017537940 A JP 2017537940A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017531478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537940A5 (enExample
Inventor
ケーラー,アンジェラ,エヌ.
ステファン,エリック
カバレロ,フランシスコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of JP2017537940A publication Critical patent/JP2017537940A/ja
Publication of JP2017537940A5 publication Critical patent/JP2017537940A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017531478A 2014-12-10 2015-12-10 増殖性疾患の処置に有用な融合1,3−アゾール誘導体 Pending JP2017537940A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090290P 2014-12-10 2014-12-10
US62/090,290 2014-12-10
PCT/US2015/065044 WO2016094688A1 (en) 2014-12-10 2015-12-10 Fused 1,3-azole derivatives useful for the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
JP2017537940A true JP2017537940A (ja) 2017-12-21
JP2017537940A5 JP2017537940A5 (enExample) 2019-02-07

Family

ID=55073117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017531478A Pending JP2017537940A (ja) 2014-12-10 2015-12-10 増殖性疾患の処置に有用な融合1,3−アゾール誘導体

Country Status (6)

Country Link
US (2) US10017520B2 (enExample)
EP (1) EP3230279A1 (enExample)
JP (1) JP2017537940A (enExample)
AU (1) AU2015360416A1 (enExample)
CA (1) CA2968884A1 (enExample)
WO (1) WO2016094688A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MY199705A (en) 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
MX2018009913A (es) 2016-02-16 2018-11-29 Massachusetts Inst Technology Aglutinantes max como moduladores myc y sus usos.
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102685249B1 (ko) 2016-06-20 2024-07-17 인사이트 코포레이션 면역조절제로서의 복소환식 화합물
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
GB201614134D0 (en) * 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018119224A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
PE20191532A1 (es) 2016-12-22 2019-10-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en) 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Pd-1/pd-l1阻害剤の塩
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
US12545654B2 (en) 2020-02-10 2026-02-10 Stemsynergy Therapeutics, Inc. MYC inhibitors and uses thereof
BR112022022409A2 (pt) 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備pd-1/pd-l1抑制劑以及其鹽及結晶形式之方法
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
WO2002051409A1 (en) * 2000-12-22 2002-07-04 Geron Corporation Telomerase inhibitors and methods of their use
JP2009501778A (ja) * 2005-07-20 2009-01-22 アバンテイス・フアルマ・エス・アー 1,4−ジヒドロピリジン縮合ヘテロ環、これらの調製法、使用およびこれらを含有する組成物
WO2011063602A1 (zh) * 2009-11-27 2011-06-03 华东理工大学 5-取代-2,4-噻唑烷二酮类化合物在制备igf1r功能调节药物中的应用
WO2012033149A1 (ja) * 2010-09-10 2012-03-15 塩野義製薬株式会社 Ampk活性化作用を有するヘテロ環縮合イミダゾール誘導体
JP2012508260A (ja) * 2008-11-10 2012-04-05 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼの阻害剤として有用な化合物
JP2013512903A (ja) * 2009-12-04 2013-04-18 サイリーン ファーマシューティカルズ インコーポレーティッド Ck2阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
WO2014159837A1 (en) * 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02191695A (ja) 1989-01-20 1990-07-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02194085A (ja) 1989-01-24 1990-07-31 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02196887A (ja) 1989-01-26 1990-08-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02208392A (ja) 1989-02-08 1990-08-17 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02222488A (ja) 1989-02-23 1990-09-05 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227490A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227489A (ja) 1989-02-28 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02227491A (ja) 1989-03-01 1990-09-10 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02242882A (ja) 1989-03-16 1990-09-27 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247280A (ja) 1989-03-20 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02247282A (ja) 1989-03-22 1990-10-03 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255794A (ja) 1989-03-29 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
JPH02255793A (ja) 1989-03-30 1990-10-16 Dainippon Ink & Chem Inc 強誘電性液晶組成物
US5965574A (en) 1996-08-13 1999-10-12 Chen; Yuhpyng Liang Heteroaryl amines as novel acetylcholinesterase inhibitors
JPH08231541A (ja) 1995-03-01 1996-09-10 Nippon Soda Co Ltd イミダゾリン誘導体および除草剤
WO2000018746A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders
AU6325799A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
JP2003057783A (ja) 2001-08-21 2003-02-26 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075955A (ja) 2001-09-03 2003-03-12 Konica Corp 銀色調を改良した光熱写真画像形成材料
JP2003075957A (ja) 2001-09-07 2003-03-12 Konica Corp スケイル模様のない光熱写真画像形成材料
MXPA04002404A (es) * 2001-09-14 2004-05-31 Novo Nordisk As Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r.
US20050042674A9 (en) * 2002-02-21 2005-02-24 Lin Yu Common ligand mimics: thiazolidinediones and rhodanines
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
AU2003291613B2 (en) * 2002-04-30 2007-09-27 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
JP4211433B2 (ja) 2002-08-14 2009-01-21 三菱化学株式会社 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子
WO2004080989A1 (ja) 2003-03-10 2004-09-23 Sumitomo Chemical Company Limited フラン化合物の製造方法
US7777051B2 (en) 2003-05-13 2010-08-17 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
EP1677794B1 (en) 2003-09-12 2014-12-03 Elixir Pharmaceuticals, Inc. Methods of treating disorder
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
WO2005033090A1 (ja) 2003-10-06 2005-04-14 Sumitomo Chemical Company, Limited 芳香族化合物
EP1768694A1 (en) * 2004-07-09 2007-04-04 Novo Nordisk A/S Phamaceutical preparations comprising insulin
JP2006084592A (ja) 2004-09-14 2006-03-30 Fuji Photo Film Co Ltd 感光性組成物
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
JP4931434B2 (ja) 2006-02-14 2012-05-16 株式会社ダイセル アミノ基含有アダマンタン誘導体とその製造方法
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
US20100009969A1 (en) 2006-07-27 2010-01-14 Ucb Pharma, S.A. Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
NZ586399A (en) 2008-01-24 2011-12-22 Ucb Pharma Sa Compounds comprising a cyclobutoxy group
CN102016590A (zh) 2008-02-28 2011-04-13 生命技术公司 荧光偏振hERG试验
WO2010058402A1 (en) * 2008-11-20 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Novel anti-biofilm agents
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
JP5046213B2 (ja) 2009-03-12 2012-10-10 独立行政法人科学技術振興機構 光学活性アルコール化合物の製法
WO2012153780A1 (ja) 2011-05-11 2012-11-15 出光興産株式会社 新規化合物、有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子
EP2757101A1 (en) 2011-09-13 2014-07-23 Idemitsu Kosan Co., Ltd Fused heterocyclic aromatic derivative, organic electroluminescence element material, and organic electroluminescence element using same
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
CN105246876B (zh) 2013-02-28 2017-06-16 住友化学株式会社 稠合杂环化合物及其有害生物防除用途
US9242944B2 (en) 2013-03-27 2016-01-26 University Of Maryland, Baltimore Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability
WO2015089180A1 (en) 2013-12-11 2015-06-18 The Scripps Research Institute Small molecule c-myc inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
WO2002051409A1 (en) * 2000-12-22 2002-07-04 Geron Corporation Telomerase inhibitors and methods of their use
JP2009501778A (ja) * 2005-07-20 2009-01-22 アバンテイス・フアルマ・エス・アー 1,4−ジヒドロピリジン縮合ヘテロ環、これらの調製法、使用およびこれらを含有する組成物
JP2012508260A (ja) * 2008-11-10 2012-04-05 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼの阻害剤として有用な化合物
WO2011063602A1 (zh) * 2009-11-27 2011-06-03 华东理工大学 5-取代-2,4-噻唑烷二酮类化合物在制备igf1r功能调节药物中的应用
JP2013512903A (ja) * 2009-12-04 2013-04-18 サイリーン ファーマシューティカルズ インコーポレーティッド Ck2阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
WO2012033149A1 (ja) * 2010-09-10 2012-03-15 塩野義製薬株式会社 Ampk活性化作用を有するヘテロ環縮合イミダゾール誘導体
WO2014159837A1 (en) * 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, JPN6019036133, 2014, pages 5693 - 5701, ISSN: 0004268792 *
NATURE CHEMICAL BIOLOGY, vol. 1(3), JPN6019036150, 2005, pages 167 - 173, ISSN: 0004268805 *
PLOS ONE, vol. 8(4), JPN6019036148, 2013, pages 1 - 9, ISSN: 0004268804 *
REGISTRY(STN), JPN7019003003, 2001, ISSN: 0004268793 *
REGISTRY(STN), JPN7019003006, 2004, ISSN: 0004268794 *
REGISTRY(STN), JPN7019003007, 2002, ISSN: 0004268795 *
REGISTRY(STN), JPN7019003008, 2002, ISSN: 0004268796 *
REGISTRY(STN), JPN7019003009, 2003, ISSN: 0004268798 *
REGISTRY(STN), JPN7019003010, 2002, ISSN: 0004268799 *
REGISTRY(STN), JPN7019003011, 2002, ISSN: 0004268800 *
REGISTRY(STN), JPN7019003012, 2002, ISSN: 0004268801 *
REGISTRY(STN), JPN7019003013, 2001, ISSN: 0004268802 *
REGISTRY(STN), JPN7019003014, 2013, ISSN: 0004268806 *
REGISTRY(STN), JPN7019003015, 2004, ISSN: 0004268808 *
REGISTRY(STN), JPN7019003016, 2013, ISSN: 0004268809 *
REGISTRY(STN), JPN7019003017, 2013, ISSN: 0004268810 *
REGISTRY(STN), JPN7019003018, 2011, ISSN: 0004268811 *
REGISTRY(STN), JPN7019003019, 2002, ISSN: 0004268812 *
REGISTRY(STN), JPN7019003020, 2004, ISSN: 0004268797 *
SYNTHETIC COMMUNICATIONS, vol. 43(14), JPN6019036147, 2013, pages 1882 - 1895, ISSN: 0004268803 *
TETRAHEDRON LETTERS, vol. 52, JPN6019036155, 2011, pages 3347 - 3352, ISSN: 0004268807 *

Also Published As

Publication number Publication date
CA2968884A1 (en) 2016-06-16
US20180291035A1 (en) 2018-10-11
AU2015360416A1 (en) 2017-06-08
US20160168165A1 (en) 2016-06-16
US10017520B2 (en) 2018-07-10
US20200048276A9 (en) 2020-02-13
WO2016094688A1 (en) 2016-06-16
EP3230279A1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
US10017520B2 (en) Myc modulators and uses thereof
US11932625B2 (en) Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
JP7308146B2 (ja) インターロイキン1受容体関連キナーゼの阻害剤およびその使用
JP6854762B2 (ja) サイクリン依存性キナーゼ7(cdk7)の阻害剤
JP6861166B2 (ja) サイクリン依存性キナーゼの阻害剤
CN113993519B (zh) 细胞周期蛋白依赖性激酶12(cdk12)的降解剂及其用途
US12415816B2 (en) Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
JP2018522867A (ja) 縮合二環式ピリミジン誘導体およびこれらの使用
JP2017512186A (ja) ジヒドロプテリジノン誘導体およびその使用
JP6788583B2 (ja) 増殖性疾患を処置するためのチアゾリル含有化合物
US10865213B2 (en) Max binders as MYC modulators and uses thereof
JP2020529998A (ja) 血漿カリクレインの阻害剤およびその使用
JP2021514955A (ja) プロテアソーム関連ユビキチン受容体rpn13機能を阻止する低分子およびその使用法
JP2021529174A (ja) Dot1lディグレーダーおよびその使用
JP7185631B2 (ja) 抗線維化化合物
US20230382865A1 (en) Histone demethylase 5 inhibitors and uses thereof
US20230339865A1 (en) Quinazoline-derived hck inhibitors for use in the treatment of myd88 mutated diseases
WO2017151625A1 (en) 4,9-dioxo-4,9-dihydronaphtho(2,3-b)furan-3-carboxmide derivatives and uses thereof for treating proliferative diseases and infectious diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200526